Tag: ATOS

Blue Horseshoe Stocks: MDCN Recap, Options Idea & More

Medican Enterprises, Inc. MDCN

In yesterday morning’s premarket report we took note of MDCN’s rebound off of a relative bottom, and speculated that the momentum built up in Tuesday’s session could carry over into added gains.

That certainly proved to be the case, as MDCN spiked heavily from its early low of .0024, running as high as .0039 shortly before 11:30AM. It marked an intraday move which provided gain opportunities of up to 62% before pulling back into the close of .0022.

We’ll go ahead and monitor this one for the remainder of the week for any potential bounce-play chances that might arise when it finds solid support. We’ll look for that to occur at or above Tuesday’s low of .0015.

Isis Pharmaceuticals, Inc. ISIS – Options Idea

ISIS appears to be in full-on breakout mode this morning, and as a result we thought we’d formulate an idea to take advantage of this via the options chain.

Given the current price and conditions caused by this morning’s catalyst (link to PR below), we’re going to be tracking the activity in the Weekly $70-73 Calls for potential intraday flip opportunities.

Extended Watchlist:
PTBI, RAD, SFUN, ATOS, AGEN, ASTI

Blue Horseshoe Stocks: CYBR, MCP, MEIP & More

CyberArk Software, Ltd. CYBR

Our first experiences with CYBR were good ones, when we successfully called a couple of potentially lucrative options trades around the middle of last month. It was in our report from February 13ththat we targeted CYBR $50 and $55 Calls, and that day we saw moves in those contracts of 72% and 165% respectively.
–
We flagged CYBR once again yesterday, which had previously been under several weeks of consolidation, yet was gapping up in the premarket. The stock did well in reversing its path, trading in a range from 50.79-55.03, and holding the majority of those gains into the close.

Our current options idea is going to be the 04/17 $50 Calls (Closed at 6.60 yesterday). Should CYBR reach its way back to the $60-level anytime in the next few weeks, the gains we see in those contracts will be quite substantial.

Molycorp, Inc. MCP

MCP appeared in yesterday’s extended watchlist and demonstrated a reversal of its own. We’re going to place MCP on more intensive watch as the week progresses, as it has the markings of a potential bottom play.

We’ve illustrated some of the key characteristics of the chart below, which appears to be gearing up for what could be a big swing. The stock ran well over a dollar at the beginning of last month, so the potential for rapid gains has certainly been demonstrated.

MEI Pharma, Inc. MEIP

We’ve also got an eye on MEIP after the stock was crushed down to a 52-week low yesterday, following the company’s announcement of the failure of its cancer drug in middle-stage testing.

A single-session depreciation on the order of 70% is the hallmark of one heck of a knee-jerk reaction, and the stock appears to be gapping up slightly this morning, so we’ll be on the lookout for a recovery in MEIP shares in coming days.

Extended Watchlist:
IMGN, ATOS ISR, HEB, GEVO, NEPT

Blue Horseshoe Stocks: Pharma Watchlist & More

Lexicon Pharmaceuticals, Inc. LXRX

We’re taking notice of LXRX this morning in the wake of a premarket PR that has the stock trending up to its highest levels of the past three months; it contained updates on current projects as well as increased earnings. The addition of an interesting setup on the chart gives us good reason to place LXRX on watch this mid-week.

As you can see on the snapshot below, the stock gapped down significantly at the end of November. In premarket activity today we’re seeing a partial fill taking place. We’re going to be watching for LXRX to fill the remainder of the gap into the mid 1.20’s where its next area of resistance will come in at the 200DMA of 1.28.

THE WOODLANDS, Texas, March 4, 2015 /PRNewswire/ — Lexicon Pharmaceuticals, Inc. (LXRX), a biopharmaceutical company focused on developing breakthrough treatments for human disease, today updated its drug development progress and reported financial results for the three months and year ended December 31, 2014.>> VIEW PR

Pharmaceutical Watchlist

There are a number of other pharma and biopharma stocks gapping up in the premarket this morning, some of which have appeared in our reports in the past. We’ve listed them below along with links to today’s news, where applicable:

Keryx Biopharmaceuticals, Inc. KERX


Atossa Genetics, Inc. ATOS


Coronado Biosciences, Inc. CNDO

Coronado Biosciences Forms New Subsidiary, Checkpoint Therapeutics, to Develop Novel Immuno-Oncology Antibodies (Wed 8:30AM EST)

PhotoMedex, Inc. PHMD

Orexigen Therapeutics, Inc. OREX

KaloBios Pharmaceuticals, Inc. KBIO

Earnings-Related Options Ideas

American Eagle Outfitters, Inc. AEO beat expected Q4 profits and revenues, and is gapping up as a result. To take advantage of the trend, we are monitoring options trading possibilities in the AEO Weekly $15-16 Calls

Abercrombie & Fitch ANF fell short of expectations with regard to sales, which is fueling a downtrend here in the premarket, so we’ll take the opposite approach here, and keep an eye on ANF Weekly $23-24 Puts.

Extended Watchlist:
IFON, PLUG, NPTN, WLT, LEI